05 November 2026
Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer
Audio Journal of Oncology Podcast
About
MADRID, Spain—The antibody-drug conjugate datopotamab deruxtecan (aTrop-2-directed antibody carrying a topoisomerase inhibitor payload) achieved clinically meaningful intracranial responses among patients with resected inoperable or metastatic triple negative breast cancer with CNS involvement in the TROPION-Breast02 study discussed at the 2026 Annual Meeting of the European Society for Medical Oncology.
Peter Goodwin heard the details from the study’s first author: Rebecca Dent MD, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre in Singapore.
Peter Goodwin heard the details from the study’s first author: Rebecca Dent MD, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre in Singapore.